Comparison of Preference for Rizatriptan 10-mg Wafer versus Sumatriptan 50-mg Tablet in Migraine

Rizatriptan (MAXALT TM , a registered trademark of Merck & Co. Inc.) is a selective 5-HT 1B/1D receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized, open-label, crossover outpatient study assessed the preference of 481 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European neurology 2001-01, Vol.45 (4), p.275-283
Hauptverfasser:	Pascual, Julio, Bussone, Gennaro, Hernandez, Jose Fernando, Allen, Christopher, Vrijens, France, Patel, Krupa
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Aged Biological and medical sciences Cross-Over Studies Female Humans Male Medical sciences Middle Aged Migraine Disorders - drug therapy Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Original Paper Patient Satisfaction Pharmacology. Drug treatments Serotonin Receptor Agonists - administration & dosage Serotonin Receptor Agonists - therapeutic use Serotoninergic system Sumatriptan - administration & dosage Sumatriptan - therapeutic use Tablets Triazoles - administration & dosage Triazoles - therapeutic use Tryptamines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!